DE
- Deutsch
DK
- Dansk
EN
- English
FI
- Suomi
FR
- Français
IT
- Italiano
NL
- Nederlands
NO
- Norsk
PL
- Polskie
SE
- Svenska
SI
- Slovenščina

Members area
Data warehouse

Clinical Trials

New diagnosis Ver-A-T1D
New diagnosis MELD-ATG
New diagnosis IMPACT
New diagnosis CFZ533

Projektin yleiskuvaus
Tietoa tyypin 1 diabeteksesta
Kliiniset keskukset
Faces of Innodia
Uutisia ja tapahtumia
Julkaisuja
Avoimet työpaikat
Members area
Data warehouse
Contact
Clinical Trials
HARVEST
Events
Media
Social Links
- Twitter
- LinkedIn
FI

Avullasi voimme taistella
tyypin 1 diabetesta vastaan

Jos lähisukulaisellasi on tyypin 1 diabetes, onko sinulla riski sairastua siihen?

Our Job opportunities

Clinical & Research Network Manager

INNODIA Timeline

2015

November
INNODIA consortium launched

2016

November
INNODIA recruits first newly diagnosed T1D subject on World Diabetes Day

2017

September
Introduction of Delta cartoon, children’s comic booklet and cartoon video by PAC

December
Recruitment capacity extension by Satellites

2018

May
1000 participants recruited

2019

January
50 publications

April
First T1D subject completed 24 mth program

June
Analysis starts of the first 100 people with newly diagnosed T1D

November
3000 participants and counting

December
INNODIA
HARVEST accepted; 4 new academic and 2 industry partners (Novartis, Imcyse) join consortium

2020

February
EMA advises positive on INNODIA's Master Protocol

June
Kick off meeting INNODIA HARVEST

December
• Start of clinical trials
• First patient treated in MELD-ATG

2021

All year
100 years discovery of Insulin

January
• First patient treated in IMPACT

February
• First patient treated in IMPACT study
• First Ver-A-T1D randomisation - Graz
• First patient treated in INNODIA with Iscalimab
• First patient treated in Ver-A-T1D

September
First 100 cohort completed

December
• Recruitment target of Newly Diagnosed PWD’s achieved in the observational study
• 100+ joint publications INNODIA & INNODIA HARVEST

2022

January
4+ new clinical trials being discussed for the near future

February
• First patient completed the Verapamil study
• First patient completed 1 year treatment with Verapamil

May
MELD-ATG trial open for the 5-11 years old

June
• INNODIA business plan for sustainability
• First two children (<12yrs) randomised in MELD-ATG

December 15^th
Iscalimab trial closed to new enrollment

2023

February
• End of recruitment in IMPACT

July
Last patient completing treatment in IMPACT

December
Anticipated end of recruitment in MELD-ATG trial

Results of first
clinical trial

First efficacy results expected in IMPACT

2024

March
Results from primary analysis in IMPACT

April
Target end of recruitment in Ver-A-T1D

September
Target end of follow-up in IMPACT

December
Anticipated last patient last visit in MELD-ATG trial

2025

April
Last patient completing treatment with Verapamil

June
First results of the MELD-ATG study presented

September
First results of Ver-A-T1D study presented

December
Results from long-term follow-up in IMPACT

Building upon the success of INNODIA and INNODIA HARVEST projects,
we established a non-profit organisation, called INNODIA iVZW.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115797 (INNODIA). This Joint Undertaking receives support from the Union’s Horizon 2020 research and innovation programme, “EFPIA”, “JDRF” and “The Leona M. and Harry B. Helmsley Charitable Trust”. The www.innodia.eu reflects only the author's view and the JU is not responsible for any use that may be made of the information it contains.

By using this website, you agree to the use of cookies.
For more information visit: Privacy policy